Paclitaxel Oral Solution (DAE HWA Pharmaceutical)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NamePaclitaxel Oral Solution (DAE HWA Pharmaceutical)
Drug Alias NameLiporaxelDHP-107RMX-3001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin depolymerization inhibitorsTubulin polymerisation promoters
TargetsTubulin
Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsStomach Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2016/09/09
Country/TerritoryCzechiaBulgariaUnited States +[7
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDae Hwa Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A